HaemoDYNAMICs in Primary and Secondary Hypertension

Summary

The primary aim of the present study was to examine the haemodynamic changes in primary hypertension and secondary hypertension (renal diseases, endocrine diseases, obesity-associated hypertension) with a non-invasive haemodynamic measurement protocol utilizing radial pulse wave analysis and whole-body impedance cardiography in both supine position and during head-up tilt. For comparison, haemodynamics of subjects with chronic fatigue syndrome will also be recorded.

Conditions

• Primary Hypertension
• Secondary Hypertension
• Aortic Stenosis
• Renal Insufficiency

Interventions

DRUG

Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)

From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).

DRUG

Salbutamol 400 µg (single dose, no longer given since January 2017)

From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).

DRUG

L-arginine (10 min infusion, no longer given since January 2017)

From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).

DIETARY_SUPPLEMENT

Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)

Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).

DIETARY_SUPPLEMENT

Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)

Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).

DRUG

Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)

Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).

Sponsors & Collaborators

• Finnish Foundation for Cardiovascular Research

  collaborator OTHER

• Paavo Nurmi Foundation

  collaborator UNKNOWN

• Sigrid Jusélius Foundation

  collaborator OTHER

• Finnish Cultural Foundation

  collaborator OTHER

• Tampere Tuberculosis Foundation

  collaborator OTHER

• Medical Research Fund of the Tampere University Hospital, Finland

  collaborator OTHER

• Aarne Koskelo Foundation

  collaborator OTHER

• Finnish Medical Foundation

  collaborator NETWORK

• Finnish Kidney Foundation

  collaborator UNKNOWN

• Päivikki and Sakari Sohlberg Foundation, Finland

  collaborator OTHER

• Tampere University

  lead OTHER

Principal Investigators

• Ilkka Pörsti, MD, PhD · Tampere University

Eligibility

Min Age

18 Years

Max Age

99 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2006-05-25

Primary Completion

2025-12-31

Completion

2025-12-31

Countries

• Finland

Study Locations